Expression of mir-29a-5p, sclerostin and fetuin-A in patients with chronic kidney disease and their correlation with vascular calcification

被引:2
作者
Ma, Xiaoying [1 ]
Sheng, Yuping [1 ]
Yang, Xingmeng [1 ]
Wang, Na [1 ]
Zhang, Haoran [1 ]
Xu, Haiping [1 ]
Sun, Fuyun [1 ]
机构
[1] Cangzhou Cent Hosp, Dept Nephrol, Cangzhou 061000, Hebei, Peoples R China
关键词
Osteosclerosis protein; fetuin A; chronic kidney disease; vascular calcification; BONE;
D O I
10.14715/cmb/2022.68.7.12
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The objective of the current study was to analyze the expression of mir-29a-5p, osteosclerotin and fetuin-A in patients with chronic kidney disease and their correlation with vascular calcification. For this purpose, 162 patients with chronic kidney disease treated in our hospital from January 2020 to January 2022 were selected retrospectively, and then 162 healthy people who underwent physical examination with our hospital in the same period were selected. The expressions of serum mir-29a-5p, sclerostin and fetuin-A were analyzed after fasting venous blood was drawn from the two groups. According to the coronary artery calcification score (C ACS), patients with chronic kidney disease were divided into the calcification group (69 cases) and the non-calcification group (93 cases). The expressions of mir-29a-5p, sclerostin and fetuin-A in the two groups were analyzed, and the correlation between the three in chronic kidney disease and vascular calcification was analyzed. Results showed that compared with the control group, the expression of mir-29a-5p and sclerostin in the study group was higher, and the expression of fetuin-A was lower, the difference was statistically significant (P < 0.05); The expression of mir-29a-5p, sclerostin and fetuin-A in calcified group was higher than that in non-calcified group, and the expression of fetuin-A was lower (P < 0.05); Mir-29a-5p and sclerostin showed positive correlation (r=6.776, P=0.011); The expression of mir-29a-5p and fetuin-A showed negative correlation (r=-5.326, P=0.001); The expression of mir-29a-5p and sclerostin showed negative correlation (r=-9.677, P=0.001); Mir-29a-5p and sclerostin were positively correlated with vascular calcification (r=0.695, P=0.001; 1=0.715, P=0.001), and fetuin-A was positively correlated with vascular calcification (r = -0.953, P = 0.001). Then, Mir-29a-5p, sclerostin and fetuin-A are abnormally expressed in chronic kidney disease. There is an abnormal correlation among them in chronic kidney disease, and they are correlated with vascular calcification. Copyright: (C) 2022 by the C.M.B. Association. All rights reserved.
引用
收藏
页码:70 / 74
页数:5
相关论文
共 21 条
  • [1] Ammirati AL, 2020, REV ASSOC MED BRAS, V66, pS3, DOI [10.1590/1806-9282.66.S1.3, 10.1590/1806-9282.66.s1.3]
  • [2] Sclerostin levels in uremic patients: a link between bone and vascular disease
    Bruzzese, Annamaria
    Lacquaniti, Antonio
    Cernaro, Valeria
    Ricciardi, Carlo Alberto
    Loddo, Saverio
    Romeo, Adolfo
    Montalto, Gaetano
    Costantino, Giuseppe
    Torre, Francesco
    Pettinato, Giuseppina
    Salamone, Ignazio
    Aloisi, Carmela
    Santoro, Domenico
    Buemi, Michele
    [J]. RENAL FAILURE, 2016, 38 (05) : 759 - 764
  • [3] Chronic kidney disease and nutrition support
    Chan, Winnie
    [J]. NUTRITION IN CLINICAL PRACTICE, 2021, 36 (02) : 312 - 330
  • [4] Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone-Vascular Axis
    De Mare, Annelies
    Maudsley, Stuart
    Azmi, Abdelkrim
    Hendrickx, Jhana O.
    Opdebeeck, Britt
    Neven, Ellen
    D'Haese, Patrick C.
    Verhulst, Anja
    [J]. TOXINS, 2019, 11 (07)
  • [5] K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword
    Eknoyan, G
    Levin, NW
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) : S14 - S266
  • [6] Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study
    Junyent, Mireia
    Martinez, Montserrat
    Borras, Merce
    Coll, Blai
    Valdivielso, Jose Manuel
    Vidal, Teresa
    Sarro, Felipe
    Roig, Jordi
    Craver, Lourdes
    Fernandez, Elvira
    [J]. BMC NEPHROLOGY, 2010, 11
  • [7] Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study
    Li, Min
    Zhou, Hua
    Yang, Min
    Xing, Changying
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (02) : 311 - 323
  • [8] Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
    Li, Xiaodong
    Ominsky, Michael S.
    Warmington, Kelly S.
    Morony, Sean
    Gong, Jianhua
    Cao, Jin
    Gao, Yongming
    Shalhoub, Victoria
    Tipton, Barbara
    Haldankar, R. J.
    Chen, Qing
    Winters, Aaron
    Boone, Tom
    Geng, Zhaopo
    Niu, Qing-Tian
    Ke, Hua Zhu
    Kostenuik, Paul J.
    Simonet, W. Scott
    Lacey, David L.
    Paszty, Chris
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2009, 24 (04) : 578 - 588
  • [9] Sleep Apnea and Chronic Kidney Disease A State-of-the-Art Review
    Lin, Chou-Han
    Lurie, Renee C.
    Lyons, Owen D.
    [J]. CHEST, 2020, 157 (03) : 673 - 685
  • [10] Marini J.C., 2000, ENDOTEXT